ABSTRACT
Background Brachial plexopathy causes pain and loss of function in the affected extremity. Entrapment of the brachial plexus terminal branches within the surrounding connective tissue, or medial brachial fascial compartment, may manifest in debilitating symptoms. Open fasciotomy and external neurolysis of the neurovascular bundle in the medial brachial fascial compartment were performed as a surgical treatment for pain and functional decline in the upper extremity. The aim of this study was to evaluate pain outcomes after surgery in patients diagnosed with brachial plexopathy. Methods We identified 21 patients who met inclusion criteria. Documents dated between 2005 and 2019 were reviewed from electronic medical records. Chart review was conducted to collect data on visual analog scale (VAS) for pain, Semmes-Weinstein monofilament test (SWMT), and Medical Research Council (MRC) scale for muscle strength. Pre- and postoperative data was obtained. A paired sample t -test was used to determine statistical significance of pain outcomes. Results Pain severity in the affected arm was significantly reduced after surgery (pre: 6.4 ± 2.5; post: 2.0 ± 2.5; p < 0.01). Additionally, there was an increased response to SWMT after the procedure. More patients achieved an MRC rating score ≥3 and ≥4 in elbow flexion after surgery. This may be indicative of improved sensory and motor function. Conclusion Open fasciotomy and external neurolysis at the medial brachial fascial compartment is an effective treatment for pain when nerve continuity is preserved. These benefits were evident in patients with a prolonged duration elapsed since injury onset.
ABSTRACT
OBJECTIVES: To investigate the length of stay for observation and treatment of neonatal abstinence syndrome (NAS), as well as the hospital costs associated with the medical care of affected newborns. METHODS: A retrospective chart review was conducted at Shands Hospital at the University of Florida, Gainesville, Florida. Data were collected for newborns diagnosed with NAS, including their hospital length of stay and the associated hospital charges, from December 1, 2008, to November 30, 2011. RESULTS: One hundred-sixty eligible newborns were included in the study. During the 3-year study period, hospital charges related to the diagnosis and treatment of NAS increased from $1.1 million per year to $1.8 million per year. Compared with the cost of caring for newborns without the risk of NAS, an additional $4.1 million was spent in the medical care of these newborns. CONCLUSIONS: The costs associated with treating newborns with NAS are exponentially higher than the costs associated with newborns not affected with NAS. The societal costs associated with treatment of newborns with NAS, as well as infant symptomatology experienced with NAS, can be reduced by encouraging physicians to be proactive in screening for drug use, urging women who use chronic opioids to actively engage in family planning and contraception, and encouraging pregnant women who use opioids to seek substance treatment.
